Dimensional Fund Advisors LP lifted its stake in shares of Regenxbio Inc (NASDAQ:RGNX) by 157.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 321,713 shares of the biotechnology company’s stock after acquiring an additional 196,944 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Regenxbio were worth $13,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in shares of Regenxbio by 37.4% during the third quarter. SG Americas Securities LLC now owns 3,422 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 931 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Regenxbio by 12.6% during the third quarter. Bank of New York Mellon Corp now owns 359,415 shares of the biotechnology company’s stock valued at $27,136,000 after purchasing an additional 40,085 shares in the last quarter. United Services Automobile Association lifted its holdings in shares of Regenxbio by 203.3% during the third quarter. United Services Automobile Association now owns 12,286 shares of the biotechnology company’s stock valued at $928,000 after purchasing an additional 8,235 shares in the last quarter. Riverhead Capital Management LLC lifted its holdings in shares of Regenxbio by 137.5% during the third quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Regenxbio by 113.5% during the third quarter. Renaissance Technologies LLC now owns 286,500 shares of the biotechnology company’s stock valued at $21,631,000 after purchasing an additional 152,300 shares in the last quarter. 82.18% of the stock is currently owned by institutional investors and hedge funds.

Shares of RGNX opened at $54.65 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.24 and a quick ratio of 15.24. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of 22.96 and a beta of 0.47. Regenxbio Inc has a 52 week low of $35.65 and a 52 week high of $85.10.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.43. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. As a group, research analysts anticipate that Regenxbio Inc will post -3.22 earnings per share for the current fiscal year.

In related news, CFO Vittal Vasista sold 10,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $60.75, for a total transaction of $607,500.00. Following the completion of the sale, the chief financial officer now owns 230,915 shares in the company, valued at $14,028,086.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Curran Simpson sold 43,832 shares of the stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $50.08, for a total value of $2,195,106.56. Following the sale, the senior vice president now owns 47,950 shares of the company’s stock, valued at approximately $2,401,336. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,200 shares of company stock valued at $4,965,802. Company insiders own 16.90% of the company’s stock.

RGNX has been the subject of a number of research reports. Raymond James upgraded Regenxbio from an “outperform” rating to a “strong-buy” rating and set a $94.00 price objective for the company in a research report on Tuesday, February 5th. ValuEngine upgraded Regenxbio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 5th. BidaskClub cut Regenxbio from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 30th. Evercore ISI upgraded Regenxbio from an “in-line” rating to an “outperform” rating and set a $51.25 price objective for the company in a research report on Monday, February 25th. Finally, Chardan Capital reiterated a “buy” rating and set a $127.50 price objective on shares of Regenxbio in a research report on Friday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. Regenxbio currently has a consensus rating of “Buy” and a consensus price target of $77.97.

TRADEMARK VIOLATION NOTICE: “Dimensional Fund Advisors LP Buys 196,944 Shares of Regenxbio Inc (RGNX)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/04/19/dimensional-fund-advisors-lp-buys-196944-shares-of-regenxbio-inc-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Further Reading: How can investors find ex-dividend dates?

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.